DNA-encapsulated magnesium phosphate nanoparticles elicit both humoral and cellular immune responses in mice

Results in Immunology

Volumn 4, Issue 1, 2014, Pages 46-53

  Bhakta, Gajadhar ^a,b   Nurcombe, Victor ^b   Maitra, Amarnath ^a   Shrivastava, Anju ^a  

^a UNIVERSITY OF DELHI   (India)

^b INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

Author keywords

Antigen presenting cells; Inorganic phosphate nanoparticles; Microemulsion; PEGFP; Vaccine

Indexed keywords

ANTIBODY; DNA; ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA INTERFERON; INTERLEUKIN 12; MAGNESIUM PHOSPHATE NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG; MACROGOL; MAGNESIUM; MAGNESIUM PHOSPHATE;

AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOASSAY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MACROPHAGE ACTIVATION; MICROEMULSION; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE; ULTRACENTRIFUGATION; ANTIGEN PRESENTING CELL; CELL INTERACTION; ENCAPSULATION; PLASMID; TH1 CELL;

EID: 84901940762     PISSN: None     EISSN: 22112839     Source Type: Journal    
DOI: 10.1016/j.rinim.2014.04.001     Document Type: Article

References (48)

1. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Medicine 2000, 6:207-210. http://www.ncbi.nlm.nih.gov/pubmed/10655111, 10.1038/72318.
2. Flynn J., Triebold K., Koller B., Bloom B. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:12013-12017. http://www.ncbi.nlm.nih.gov/pubmed/1465432, 10.1073/pnas.89.24.12013.
3. Bojang K.A., Milligan P.J., Pinder M., Vigneron L., Alloueche A., Kester K.E., et al. Efficacy of RTS, S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia:a randomised trial. Lancet 2001, 358:1927-1934. http://www.ncbi.nlm.nih.gov/pubmed/11747915, 10.1016/S0140-6736(01)06957-4.
4. Tyagi R.K., Garg N.K., Sahu T. Vaccination strategies against malaria: novel carrier(s) more than a tour de force. Journal of Controlled Release: Official Journal of the Controlled Release Society 2012, 162:242-254. http://www.ncbi.nlm.nih.gov/pubmed/22564369, 10.1016/j.jconrel.2012.04.037.
5. Kathuria N., Kraynyak K.A., Carnathan D., Betts M., Weiner D.B., Kutzler M.A. Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvant. Human Vaccines andImmunotherapeutics 2012, 8:1607-1619. http://www.ncbi.nlm.nih.gov/pubmed/23151454, 10.4161/hv.22574.
6. Heller L.C., Ugen K., Heller R. Electroporation for targeted gene transfer. Expert Opinion on Drug Delivery 2005, 2:255-268. http://www.ncbi.nlm.nih.gov/pubmed/16296752, 10.1517/17425247.2.2.255.
7. Herweijer H., Wolff J.A. Progress and prospects: naked DNA gene transfer and therapy. Gene Therapy 2003, 10:453-458. http://www.ncbi.nlm.nih.gov/pubmed/12621449, 10.1038/sj.gt.3301983.
8. Kim I.S., Lee S.K., Park Y.M., Lee Y.B., Shin S.C., Lee K.C., et al. Physicochemical characterization of poly(L-lactic acid) and poly(D,L-lactide-co-glycolide) nanoparticles with polyethylenimine as gene delivery carrier. International Journal of Pharmaceutics 2005, 298:255-262. http://www.ncbi.nlm.nih.gov/pubmed/15941631, 10.1016/j.ijpharm.2005.04.017.
9. Kumar M., Mohapatra S.S., Kong X., Jena P.K., Bakowsky U., Lehr C.M. Cationic poly(lactide-co-glycolide) nanoparticles as efficient in vivo gene transfection agents. Journal of Nanoscience and Nanotechnology 2004, 4:990-994. http://www.ncbi.nlm.nih.gov/pubmed/15656192, 10.1166/jnn.2004.130.
10. Chuang V.T.G., Kragh-Hansen U., Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharmaceutical Research 2002, 19:569-577. http://www.ncbi.nlm.nih.gov/pubmed/12069157, 10.1023/A:1015396825274.
11. Cambridge C.D., Singh S.R., Waffo A.B., Fairley S.J., Dennis V.A. Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles. International Journal of Nanomedicine 2013, 8:1759-1771. http://www.ncbi.nlm.nih.gov/pubmed/23690681.
12. Eroglu E., Tiwari P.M., Waffo A.B., Miller M.E., Vig K., Dennis V.A., et al. A nonviral pHEMA+chitosan nanosphere-mediated high-efficiency gene delivery system. International Journal of Nanomedicine 2013, 8:1403-1415. http://www.ncbi.nlm.nih.gov/pubmed/23610520.
13. Carrillo C., Sanchez-Hernandez N., Garcia-Montoya E., Perez-Lozano P., Sune-Negre J.M., Tico J.R., et al. DNA delivery via cationic solid lipid nanoparticles (SLNs). European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 2013, 49:157-165. http://www.ncbi.nlm.nih.gov/pubmed/23454134, 10.1016/j.ejps.2013.02.011.
14. Saljoughian N., Zahedifard F., Doroud D., Doustdari F., Vasei M., Papadopoulou B., et al. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice. Parasite Immunology 2013, 35:397-408. http://www.ncbi.nlm.nih.gov/pubmed/23710803.
15. Gluck R., Moser C., Metcalfe I.C. Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert Opinion on Biological Therapy 2004, 4:1139-1145. http://www.ncbi.nlm.nih.gov/pubmed/15268680, 10.1517/14712598.4.7.1139.
16. McKeever U., Barman S., Hao T., Chambers P., Song S., Lunsford L., Hsu Y.Y., Roy K., Hedley M.L. Protective immune responses elicited in mice by immunization with formulations of poly(lactide-co-glycolide) microparticles. Vaccine 2002, 20:1524-1531. http://www.ncbi.nlm.nih.gov/pubmed/11858858, 10.1016/S0264-410X(01)00509-6.
17. Shack J., Thompsett J.M. The interaction of ions and desoxypentose nucleic acid of calf thymus. Journal of Biological Chemistry 1953, 203:373-387. http://www.ncbi.nlm.nih.gov/pubmed/13069521.
18. He Q., Mitchell A., Morcol T., Bell S.J.D. Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clinical and Diagnostic Laboratory Immunology 2002, 9:1021-1024. http://www.ncbi.nlm.nih.gov/pubmed/12204953.
19. He Q., Johnson S., Lagner-Bartak C.W., Morcol T., Bell S.J.D. Calcium phosphate nanoparticles as adjuvant. Clinical and Diagnostic Laboratory Immunology 2000, 7:899.
20. Maitra A. Calcium phosphate nanoparticles: second-generation nonviral vectors in gene therapy. Expert Review of Molecular Diagnostics 2005, 5:893-905. http://www.ncbi.nlm.nih.gov/pubmed/16255631, 10.1586/14737159.5.6.893.
21. Bisht S., Bhakta G., Mitra S., Maitra A. pDNA loaded calcium phosphate nanoparticles: highly efficient non-viral vector for gene delivery. International Journal of Pharmaceutics 2005, 288:157-168. http://www.ncbi.nlm.nih.gov/pubmed/15607268, 10.1016/j.ijpharm.2004.07.035.
22. Roy I., Mitra S., Maitra A., Mozumdar S. Calcium phosphate nanoparticles as novel non-viral vectors for targeted gene delivery. International Journal of Pharmaceutics 2003, 250:25-33. http://www.ncbi.nlm.nih.gov/pubmed/12480270, 10.1016/S0378-5173(02)00452-0.
23. Singh M., Briones M., Ott G., O'Hagan D. Cationic microparticles:a potent delivery system for DNA vaccines. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:811-816. http://www.ncbi.nlm.nih.gov/pubmed/10639162, 10.1073/pnas.97.2.811.
24. Moghimi S.M., Hawley A.E., Christy N.M., Gray T., Illum L., Davis S.S. Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. FEBS Letters 1994, 344:25-30. http://www.ncbi.nlm.nih.gov/pubmed/8181558, 10.1016/0014-5793(94)00351-3.
25. Hawley A.E., Illum L., Davis S.S. Lymph node localisation of biodegradable nanospheres surface modified with poloxamer and poloxamine block co-polymers. FEBS Letters 1997, 400:319-323. http://www.ncbi.nlm.nih.gov/pubmed/9009222, 10.1016/S0014-5793(96)01408-1.
26. Bhakta G., Mitra S., Maitra A. DNA encapsulated magnesium and manganous phosphate nanoparticles: potential non-viral vectors for gene delivery. Biomaterials 2005, 26:2157-2163. http://www.ncbi.nlm.nih.gov/pubmed/15576191, 10.1016/j.biomaterials.2004.06.039.
27. Bhakta G., Shrivastava A., Maitra A. Magnesium phosphate nanoparticles can be efficiently used in vitro and in vivo as non-viral vectors for targeted gene delivery. Journal of Biomedical Nanotechnology 2009, 5:106-114. http://www.ncbi.nlm.nih.gov/pubmed/20055113, 10.1166/jbn.2009.029.
28. Zhao K., Shi X., Zhao Y., Wei H., Sun Q., Huang T., et al. Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles. Vaccine 2011, 29:8549-8556. http://www.ncbi.nlm.nih.gov/pubmed/21945253, 10.1016/j.vaccine.2011.09.029.
29. Gambotto A., Dworacki G., Cicinnati V., Kenniston T., Steitz J., Tuting T., et al. Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope. Gene Therapy 2000, 7:2036-2040. http://www.ncbi.nlm.nih.gov/pubmed/11175316, 10.1038/sj.gt.3301335.
30. Steitz J., Soloff A.C., Barratt-Boyes S.M., Alber S.M., Watkins S.C., Okada H., et al. BALB/c EGFP mice are tolerant against immunization utilizing recombinant adenoviral-based vectors encoding EGFP:a novel model for the study of tolerance mechanisms and vaccine efficacy. Molecular immunology 2010, 47:1149-1153. http://www.ncbi.nlm.nih.gov/pubmed/20022379, 10.1016/j.molimm.2009.11.018.
31. Landi E., Logroscino G., Proietti L., Tampieri A., Sandri M., Sprio S. Biomimetic MG-substituted hydroxyapatite: from synthesis to in vivo behaviour. Journal of Materials Science: Materials in Medicine 2008, 19:239-247. http://www.ncbi.nlm.nih.gov/pubmed/17597369, 10.1007/s10856-006-0032-y.
32. Ryu H.S., Hong K.S., Lee J.K., Kim D.J., Lee J.H., Chang B.S., et al. Magnesia-doped HA/beta-TCP ceramics and evaluation of their biocompatibility. Biomaterials 2004, 25:393-401. http://www.ncbi.nlm.nih.gov/pubmed/14585687, 10.1016/S0142-9612(03)00538-6.
33. http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm261491.htm.
34. Baldwin S.L., D'Souza C.D., Orme I.M., Liu M.A., Huygen K., Denis O., et al. Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A. Tubercle and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease 1999, 79:251-259. http://www.ncbi.nlm.nih.gov/pubmed/10692994, 10.1054/tuld.1998.0196.
35. Meerak J., Wanichwecharungruang S.P., Palaga T. Enhancement of immune response to a DNA vaccine against Mycobacterium tuberculosis Ag85B by incorporation of an autophagy inducing system. Vaccine 2013, 31:784-790. http://www.ncbi.nlm.nih.gov/pubmed/23228812, 10.1016/j.vaccine.2012.11.075.
36. Hommelgaard A.M., Roepstorff K., Vilhardt F., Torgersen M.L., Sandvig K., van Deurs B. Caveolae: stable membrane domains with a potential for internalization. Traffic 2005, 6:720-724. http://www.ncbi.nlm.nih.gov/pubmed/16101676, 10.1111/j.1600-0854.2005.00314.x.
37. Heath W.R., Carbone F.R. Cross-presentation, dendritic cells, tolerance and immunity. Annual Review of Immunology 2001, 19:47-64. http://www.ncbi.nlm.nih.gov/pubmed/11244030, 10.1146/annurev.immunol.19.1.47.
38. Houde M., Bertholet S., Gagnon E., Brunet S., Goyette G., Laplante A., et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003, 425:402-406. http://www.ncbi.nlm.nih.gov/pubmed/14508490, 10.1038/nature01912.
39. Johannes L., Lamaze C. Clathrin-dependent or not: is it still the question?. Traffic 2002, 3:443-451. http://www.ncbi.nlm.nih.gov/pubmed/12047552, 10.1034/j.1600-0854.2002.30701.x.
40. Aderem A., Underhill D.M. Mechanisms of phagocytosis in macrophages. Annual Review of Immunology 1999, 17:593-623. http://www.ncbi.nlm.nih.gov/pubmed/10358769, 10.1146/annurev.immunol.17.1.593.
41. Rock K.L., Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunological Reviews 2005, 207:166-183. http://www.ncbi.nlm.nih.gov/pubmed/16181335, 10.1111/j.0105-2896.2005.00301.x.
42. Gamvrellis A., Leong D., Hanley J.C., Xiang S.D., Mottram P., Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunology and Cell Biology 2004, 82:506-516. http://www.ncbi.nlm.nih.gov/pubmed/15479436, 10.1111/j.0818-9641.2004.01271.x.
43. Foti M., Granucci F., Ricciardi-Castagnoli P. A central role for tissue-resident dendritic cells in innate responses. Trends in Immunology 2004, 25:650-654. http://www.ncbi.nlm.nih.gov/pubmed/15530834, 10.1016/j.it.2004.10.007.
44. Xiang S.D., Scholzen A., Minigo G., David C., Apostolopoulos V., Mottram P.L., et al. Pathogen recognition and development of particulate vaccines: does size matter?. Methods 2006, 40:1-9. http://www.ncbi.nlm.nih.gov/pubmed/16997708, 10.1016/j.ymeth.2006.05.016.
45. Lechardeur D., Lukacs G.L. Intracellular barriers to non-viral gene transfer. Current Gene Therapy 2002, 2:183-194. http://www.ncbi.nlm.nih.gov/pubmed/12109215, 10.2174/1566523024605609.
46. Otten G.R., Doe B., Schaefer M., Chen M., Selby M.J., Goldbeck C., et al. Relative potency of cellular and humoral immune responses induced by DNA vaccination. Intervirology 2000, 43:227-232. http://www.ncbi.nlm.nih.gov/pubmed/11251378, 10.1159/000053990.
47. Cherif M.S., Shuaibu M.N., Kurosaki T., Helegbe G.K., Kikuchi M., Yanagi T., et al. Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration. Vaccine 2011, 29:9038-9050. http://www.ncbi.nlm.nih.gov/pubmed/21939717, 10.1016/j.vaccine.2011.09.031.
48. Dubensky T.W., Ulmer J.B. Delivery systems for gene-based vaccines. Molecular Medicine 2000, 6:723-732. http://www.ncbi.nlm.nih.gov/pubmed/11071268.